Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Bayer Facility Stays in Berkeley, Slated for Improvements
 

Bayer HealthCare announced that it will invest $100 million to upgrade its biotech manufacturing facility in Berkeley, CA, allaying the fears of some local and state officials that the company might move production elsewhere. Earlier this year Bayer indicated that it was planning a move to the east coast.

The Berkeley facility manufactures Kogenate® FS, Bayer’s recombinant factor VIII product. Kogenate® FS is indicated for the control and prevention of bleeding episodes and perioperative management in adults and children (0-16 years old) with hemophilia A. It is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no pre-existing joint damage.

Planned enhancements made to the Berkeley site will include a new manufacturing process that will be employed in the production of future versions of Kogenate® FS.

“The investment is both an endorsement of our strong biotechnology expertise and also a mandate to become globally competitive in biotechnology manufacturing,” said Joerg Heidrich, senior vice president of Bayer HealthCare’s global product supply biotech organization and head of the Berkeley facility. “I'm very pleased and excited to invest more than $100 million in the Berkeley site to manufacture a new process for hemophiliacs.”

Source: Contra Costa Times, September 16, 2009